Overcoming of doxorubicin resistance in breast cancer cells by cationic peptides
Authors:
- Anna A LushnikovaALAnna A Lushnikova
- Anastasia V OnyanAOAnastasia V Onyan
- Anna A RudakovaARAnna A Rudakova
- Alexandr V KostarevAKAlexandr V Kostarev
- Kseniya V KozhikhovaKKKseniya V Kozhikhova
- Sergey M AndreevSASergey M Andreev
- Natalya I MoiseevaNMNatalya I Moiseeva
- Mariya A BaryshnikovaMBMariya A Baryshnikova
Open Access
- 30 October 2019
- journal article
- Published by MedCrave Group Kft. in Journal of Cancer Prevention & Current Research
- Vol. 10 (5) , 62-65
Abstract
Background: Acquired resistance to various drugs is an obstacle to anticancer therapy. Doxorubicin (Dox) is the first-line chemo-drug for therapy of various malignant tumors but it fails when treatment of multi-drug resistant tumors. One of the main factors of Dox-resistance is overexpression of drug resistance genes, particularly, P-glycoprotein – Pgp. Earlier we’ve revealed a high selective apoptosis of tumor cells, induced by some cationic peptides (CPs) in vitro through inactivation their cell targets – chaperone proteins nucleolin/NCL and nucleophosmin/NPM. This paper describes effect of CPs on breast cancer (BC) cell lines HBL 100 and doxorubicin-resistant cell line HBL-100/Dox. Objective: Is to examine the viability of BC and Dox-resistant BC cells after incubation with some CPs. Results: Some Arg/Lys-enriched cationic peptides under study induce cell death by nucleolar stress mechanisms both in HBL 100 BC cell line and HBL 100/ID 120 one. So, this CPs is perspective agents for inducing apoptosis of BC cells and overcoming Dox resistance.Keywords
This publication has 5 references indexed in Scilit:
- Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligandsDrug Discovery Today, 2019
- Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor MicroenvironmentMolecular Pharmaceutics, 2019
- Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cellsInternational Journal of Nanomedicine, 2016
- The roles of nucleolin subcellular localization in cancerBiochimie, 2015
- Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatinBlood, 2007